American ginseng Panax quinquefolius L.
Also called: North American ginseng, Wisconsin ginseng, Panax quinquefolius
American ginseng (Panax quinquefolius) is native to temperate forest regions of North America, from Quebec and Ontario south to Mississippi, Arkansas and Georgia. Its dried root is used as an herbal medicine; wild plants are now rare, so commercial root comes from cultivated plants.
- Category
- Botanical
- Part used
- Root (dried)
- Strongest evidence
- B Some positive trials
- Native range
- Native range (POWO): temperate forest regions of North America, from Quebec and Ontario in the north to Mississippi, Arkansas and Georgia in the south
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2025 meta-analysis pooled nine RCTs (952 heart-failure patients); eight added Xinyue Capsule, an oral saponin extract of American ginseng stems and leaves, alone to routine treatment, and one also added the multi-herb Qiliqiangxin capsule. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BHeart and blood vessels1 topic
BCancer1 topic
CLungs and airways1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Common colds in healthy adults (taken preventively) | C | A 2011 review of five trials (747 participants, all of North American ginseng) found insufficient evidence on cold incidence or severity; two pooled trials showed colds or respiratory infections 6.2 days shorter. [1] |
| Cancer-related fatigue | B | A double-blind RCT of 364 fatigued cancer survivors found 2,000 mg/day for 8 weeks improved fatigue scores versus placebo at 8 weeks; the 4-week difference was not significant (P = .07). [2] |
| Heart failure (Xinyue Capsule, a saponin extract of American ginseng stems and leaves, added to standard care) | B | A 2025 meta-analysis of nine RCTs (952 patients; one also added a multi-herb capsule) found higher ejection fraction and walking distance and lower BNP/NT-proBNP with add-on saponin; authors advised cautious interpretation. [3] |
Main constituents: Ginsenosides (eight major ginsenosides identified by HPLC-UV in Panax samples, including P. quinquefolius) [7]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 2,000 mg/day of American ginseng for 8 weeks in the cancer-related fatigue trial. [2]
- Cold trials gave root extract preventively for 8 to 16 weeks. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely to cause clinically apparent liver injury (Ginseng chapter, last updated March 14, 2018 …
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines3 listed
Warfarin; Blood thinners and digoxin; Drugs metabolized by CYP3A4 (e.g. imatinib, raltegravir)
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notifications2 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada, Panax quinquefolius monograph (January 30, 2026), adults 18 and older: 0.5-12 g dried root per day (glucose, restlessness/nervousness …
Details and sources
- In the 364-person fatigue trial, toxicities by self-report and CTCAE grading did not differ significantly between ginseng and placebo. [2]
- LiverTox's Ginseng chapter (written mainly about Panax ginseng; it says American ginseng has similar properties) gives likelihood score E: ginseng alone has not been linked to liver injury. Liver injury was reported when ginseng was added to imatinib or raltegravir. [4]
- Health Canada label warning: ask a health care practitioner before use if you have diabetes. [5]
Interactions
| With | What happens |
|---|---|
| Warfarin | In a randomized, double-blind, placebo-controlled trial in 20 healthy people, American ginseng lowered peak INR and warfarin levels; the authors concluded it reduces warfarin's anticoagulant effect. [6] |
| Blood thinners and digoxin | Health Canada label warning: ask a health care practitioner before use if taking blood thinners or digoxin. [5] |
| Drugs metabolized by CYP3A4 (e.g. imatinib, raltegravir) | LiverTox: some ginsenosides may inhibit CYP3A4 enough to change metabolism of other drugs (Ginseng chapter, mainly about Panax ginseng). [4] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- A 2026 study found P. ginseng and P. quinquefolius roots so anatomically similar that microscopy alone struggled to separate them; HPLC-UV showed the adulterants Codonopsis pilosula and Platycodon grandiflorus lack the eight major ginsenosides. [7]
- CITES annotation #3 covers whole and sliced roots and parts of roots, excluding manufactured parts or derivatives such as powders, pills, extracts, tonics, teas and confectionery. [8]
Regulatory status
- US: FDA's published NDI notification list has 2 entries naming Panax quinquefolius (earliest NDI 374 submitted 2006-01-18; most recent NDI 729 submitted 2011-09-15). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [9]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [10]
- International trade: listed in CITES Appendix II (current listing effective 12 June 2013, annotation #3). [8]
- Canada: Health Canada's Panax quinquefolius monograph (January 30, 2026) includes the claim 'Used in Herbal Medicine as supportive therapy for the promotion of healthy (blood) glucose/sugar levels'. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 2 entries naming Panax quinquefolius (earliest NDI 374 submitted 2006-01-18; most recent NDI 729 submitted 2011-09-15). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- NTP TR-567 (September 2011): 2-year gavage studies of ginseng root extract at 1,250, 2,500 or 5,000 mg/kg found no evidence of carcinogenic activity in male or female F344/N rats or B6C3F1 mice. The abstract does not name the Panax species; Panax ginseng and Panax quinquefolius are listed among its synonyms. [P4]
- No IARC evaluation of American ginseng (Panax quinquefolius) was found (IARC Monographs list of classifications, list data last updated 2026-07-23, checked 2026-10-29). [P5]
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely to cause clinically apparent liver injury (Ginseng chapter, last updated March 14, 2018; written mainly about Panax ginseng, it says American ginseng has similar properties). Liver injury was reported when ginseng was added to imatinib or raltegravir. [P6]
Interactions with medicines
- Warfarin: In a randomized, double-blind, placebo-controlled trial in 20 healthy people, American ginseng lowered peak INR and warfarin levels; the authors concluded it reduces warfarin's anticoagulant effect. [P7]
- Blood thinners and digoxin: Health Canada label warning: ask a health care practitioner before use if taking blood thinners or digoxin. [P8]
- Drugs metabolized by CYP3A4 (e.g. imatinib, raltegravir): LiverTox: some ginsenosides may inhibit CYP3A4 enough to change metabolism of other drugs (Ginseng chapter, mainly about Panax ginseng). [P6]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- A 2026 study of four Panax species, including P. quinquefolius, names Codonopsis pilosula and Platycodon grandiflorus as common adulterants; both lacked the eight major ginsenosides found in Panax samples. [P1]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P9]
- Microscopy of root or powder combined with HPLC-UV ginsenoside profiling — P. ginseng and P. quinquefolius roots are anatomically very similar, so microscopy alone is challenging; the study recommends integrating microscopy with chemical profiling, which also flags ginsenoside-free adulterants. [P1]
Supply and conservation
- CITES Appendix II (current listing effective 12 June 2013); annotation #3 covers whole and sliced roots and parts of roots, excluding manufactured parts or derivatives such as powders, pills, extracts, tonics, teas and confectionery. [P10]
- The species was included in CITES Appendix II in 1975 (U.S. Fish and Wildlife Service export advice, September 1, 2022). [P11]
- Kew (POWO): considered threatened in 16 US states and endangered in a further 10; wild ginseng is still harvested in Wisconsin, Pennsylvania and New York State, but it is now rare in the wild and commercial material has to come from cultivated plants. [P12]
- GBIF species API returns IUCN Red List category Not Evaluated (NE) for Panax quinquefolius, retrieved 2026-10-29; POWO also states it is not yet assessed against IUCN Red List criteria. [P13]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada, Panax quinquefolius monograph (January 30, 2026), adults 18 and older: 0.5-12 g dried root per day (glucose, restlessness/nervousness and digestion claims); 1-3 g dried root per day as non-standardized ethanolic extracts or 6-9 g per day as aqueous extracts, not over 3 g per single dose (adaptogen claims); 2.4-9 g dried root per day (Traditional Chinese Medicine decoction). [P8]
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Külkamp J, Osman AG, Katragunta K, Avula B, Khan IA, Chittiboyina AG. Microscopy combined with LC-UV analysis as a tool for authentication of ginseng species used in traditional medicine and detection of their adulterants. J Diet Suppl 2026;23(4):475-489 (PMID 42262747), 2026-06-09. pubmed.ncbi.nlm.nih.gov
- Wang J, Chang T, Liang Z, et al. The efficacy and safety of panax quinquefolius saponin for heart failure: a systematic review and meta-analysis. Front Pharmacol 2025;16:1463609 (PMID 40093323), 2025-02-28. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- National Toxicology Program. TR-567: Toxicology and Carcinogenesis Studies of Ginseng (CASRN 50647-08-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (September 2011), 2011-09. ntp.niehs.nih.gov
- IARC Monographs. List of Classifications (list data last updated 2026-07-23; retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
- NIH LiverTox (NIDDK). Ginseng (Last Update: March 14, 2018), 2018-03-14. ncbi.nlm.nih.gov
- Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004;141(1):23-7 (PMID 15238367), 2004-07-06. pubmed.ncbi.nlm.nih.gov
- Health Canada, NNHPD. Monograph: Panax quinquefolius (American ginseng) (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- CITES/UNEP-WCMC Species+. Panax quinquefolius, taxon concept 16143 (retrieved October 29, 2026), 2026-10-29. speciesplus.net
- U.S. Fish and Wildlife Service, Division of Scientific Authority. General advice for the export of wild and wild-simulated American ginseng (Panax quinquefolius) roots (September 1, 2022), hosted by CITES, 2022-09-01. cites.org
- Plants of the World Online (Royal Botanic Gardens, Kew). Panax quinquefolius L. (retrieved October 29, 2026), 2026-10-29. powo.science.kew.org
- GBIF species API: IUCN Red List category for Panax quinquefolius L. (usageKey 5372246), 2026-10-29. api.gbif.org
Sources
- Seida JK, Durec T, Kuhle S. North American (Panax quinquefolius) and Asian ginseng (Panax ginseng) preparations for prevention of the common cold in healthy adults: a systematic review. Evid Based Complement Alternat Med 2011;2011:282151 (PMID 19592479), 2011-02-14. pubmed.ncbi.nlm.nih.gov
- Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 2013;105(16):1230-8 (PMID 23853057), 2013-08-21. pubmed.ncbi.nlm.nih.gov
- Wang J, Chang T, Liang Z, et al. The efficacy and safety of panax quinquefolius saponin for heart failure: a systematic review and meta-analysis. Front Pharmacol 2025;16:1463609 (PMID 40093323), 2025-02-28. pubmed.ncbi.nlm.nih.gov
- NIH LiverTox (NIDDK). Ginseng (Last Update: March 14, 2018), 2018-03-14. ncbi.nlm.nih.gov
- Health Canada, NNHPD. Monograph: Panax quinquefolius (American ginseng) (dated January 30, 2026), 2026-01-30. webprod.hc-sc.gc.ca
- Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004;141(1):23-7 (PMID 15238367), 2004-07-06. pubmed.ncbi.nlm.nih.gov
- Külkamp J, Osman AG, Katragunta K, Avula B, Khan IA, Chittiboyina AG. Microscopy combined with LC-UV analysis as a tool for authentication of ginseng species used in traditional medicine and detection of their adulterants. J Diet Suppl 2026;23(4):475-489 (PMID 42262747), 2026-06-09. pubmed.ncbi.nlm.nih.gov
- CITES/UNEP-WCMC Species+. Panax quinquefolius, taxon concept 16143 (retrieved October 29, 2026), 2026-10-29. speciesplus.net
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (Royal Botanic Gardens, Kew). Panax quinquefolius L. (retrieved October 29, 2026), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · Ashwagandha · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.